# Discuss methylphenidate as an adult

Published by Pawel Jozefiak. [About this project](https://adhd100.jock.pl/about/), [How we check sources](https://adhd100.jock.pl/methodology/)

- Canonical: https://adhd100.jock.pl/discuss-methylphenidate-adult/
- Language: en
- First published: 2026-09-29
- Evidence checked: 2026-09-29, using AI-assisted source verification
- Clinical review: Not clinically reviewed
- Number 2 of 100 in the list: https://adhd100.jock.pl/#discuss-methylphenidate-adult

A guideline medicine for adults, with evidence that it improves symptoms in the short term.

**The number:** Adults: small improvement in self-rated symptoms vs placebo over about 12 weeks (SMD 0.343) ([BMJ / Gosling et al., 2025](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv))

## The evidence

- How sure: Certainty of evidence: High certainty. Measured in people with ADHD.
- See this comparison on the evidence map: https://adhd100.jock.pl/evidence/#r-methylphenidate-adult-core-adhd-symptoms-self-rated-short
- Evidence grade: A. Grade A: moderate or high certainty evidence in people with ADHD, or an explicit ADHD guideline recommendation.
- Basis: EBI re-estimation: 13 trials, 2944 adults, short term self-ratings; NICE NG87 1.7.11 first-line medicine
- Outcome: self-rated core ADHD symptom improvement in adults
- Comparison: vs placebo
- Benefit: 89/100. The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you.

## Why it matters

Methylphenidate acts on brain signalling involved in attention and behaviour. In EBI, adults rated their own symptoms 0.343 SMD better than on placebo, with high certainty, and the clinicians' ratings of improvement carry moderate certainty. The trials ran about 12 weeks or to their endpoint, so long term benefit is not established. NICE lists it with lisdexamfetamine as a first-line medicine for adults, yet more people left the trials because of adverse effects than on placebo, which is why the choice is a talk about benefits and harms.

## How to do it

1. Ask your ADHD clinician plainly whether methylphenidate suits you.
2. Say which parts of work, study or home life you want treatment to improve.
3. Go through your medical history, any other medicines, and what worries you about side effects.
4. Before you leave, find out what to bring to follow-up and who to contact between appointments.

## Talk to a clinician first

Whether it suits you, and the prescribing, are decisions for a qualified clinician. Bring your health history and every medicine you take, including ones bought without a prescription.

## Putting it into practice

### Start now

- 1 minute: Jot down the moment in an ordinary day you would most like treatment to improve.
- 5 minutes: Write a few treatment goals and your questions about side effects.
- 15 minutes: Put your medicine list and medical history on one page for the prescribing appointment.

### What it looks like

- Say whether your goal is getting essential work finished or keeping up with conversations.
- Ask how the review will look at unwanted effects as well as benefits.

### Common mistakes

- A bigger prescription is not the goal. Talk about how much it actually helps and how well you tolerate it.
- Short term symptom improvement does not guarantee every life difficulty will resolve; keep other support in the plan.

### A structured start

**Discuss an individual treatment trial**

1. Bring goals and relevant health information.
2. Ask the clinician about suitability, alternatives and follow-up.
3. Review changes in functioning and adverse effects together.

### Trusted how-to guides

- [Common questions about methylphenidate for adults](https://www.nhs.uk/medicines/methylphenidate-adults/common-questions-about-methylphenidate-for-adults/), NHS
- [Tips for Talking With a Health Care Provider About Your Mental Health](https://www.nimh.nih.gov/health/publications/tips-for-talking-with-your-health-care-provider), NIMH

## Sources

- [EBI-ADHD: companion data to Gosling et al., BMJ 2025, commit 86eff22a9ffb](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv), BMJ / Gosling et al., 2025 (Tier 1 guideline)
- [Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making](https://pmc.ncbi.nlm.nih.gov/articles/PMC12651917/), BMJ, 2025 (Tier 1 guideline)
- [Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations), NICE, 2019 (Tier 1 guideline)
- [Common questions about methylphenidate for adults](https://www.nhs.uk/medicines/methylphenidate-adults/common-questions-about-methylphenidate-for-adults/), NHS, 2025 (Tier 1 guideline)

---

General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician.

Report an error: meet@jock.pl

Reuse: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/